Education
About Us
Working with TipRanks
Follow Us
Gridai Technologies Corp. (GRDX)
NASDAQ:GRDX
GRDX Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
GridAI Technologies News
GRDX FAQ
What was Gridai Technologies Corp.’s price range in the past 12 months?
Gridai Technologies Corp. lowest stock price was $0.97 and its highest was $5.84 in the past 12 months.
What is Gridai Technologies Corp.’s market cap?
Gridai Technologies Corp.’s market cap is $9.38M.
When is Gridai Technologies Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Gridai Technologies Corp.’s earnings last quarter?
Currently, no data Available
Is Gridai Technologies Corp. overvalued?
According to Wall Street analysts Gridai Technologies Corp.’s price is currently Undervalued.
Does Gridai Technologies Corp. pay dividends?
Gridai Technologies Corp. does not currently pay dividends.
What is Gridai Technologies Corp.’s EPS estimate?
Gridai Technologies Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gridai Technologies Corp. have?
Gridai Technologies Corp. has 3,361,903 shares outstanding.
What happened to Gridai Technologies Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Gridai Technologies Corp.?
Currently, no hedge funds are holding shares in GRDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gridai Technologies Corp.
GridAI Technologies Corp. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its pipeline includes Latiglutenase, Capeserod, Adrulipase, and Niclosamide. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Ownership Overview
0.51%
Insiders
0.52%
Mutual Funds
0.35% Other Institutional Investors
98.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---